Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
Gallay, Philippe
Display my h-index
Publications in VIVO
 
    Export Publications Table
co-author
Co-author Network
map of science
Map of Science
Biosketch in .docx format  Create Biosketch

Gallay, Philippe

Faculty Member
share the uri qr icon Close

Positions

  • 2017 - Professor of Immunology and Microbiology, Immunology and Microbiology , Scripps Research
  • 1997 - 2017 Professor of Immunology and Microbial Science, Immunology and Microbial Science (IMS) , Scripps Research
Dr. Philippe Gallay looks at the glycoprotein attachment receptors on human cells that enhance the entry of HIV and works toward using those proteins as a guide for drug design.

Contact

  • gallay@scripps.edu

Websites

  • Philippe Gallay, Ph.D.
  • Gallay Laboratory
  • Publications
  • Research
  • Background
  • Contact
  • View All
scroll to property group menus

Publications

recent publications
  • All Publications
  • PubMed Display for Export
  • Publications without PubMed PMIDs

  • academic article

    • Kuo, J., Bobardt, M., Chatterji, U., Mayo, P. R., Trepanier, D. J., Foster, R. T., Gallay, P., Ure, D. R. A pan-cyclophilin inhibitor, CRV431, decreases fibrosis and tumor development in chronic liver disease models Journal of Pharmacology and Experimental Therapeutics  2019 371:231-241  DOI:10.1124/jpet.119.261099  PMID:31406003  PMCID:PMC6815936
    • Kuo, J., Serrano, S. S., Gronberg, A., Massoumi, R., Hansson, M. J., Gallay, P. Cyclophilin inhibitor NV556 reduces fibrosis and hepatocellular carcinoma development in mice with non-alcoholic steatohepatitis Frontiers in Pharmacology  2019 10  DOI:10.3389/fphar.2019.01129
    • Gallay, P., Ure, D., Bobardt, M., Chatterji, U., Ou, J., Trepanier, D., Foster, R. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice PLoS One  2019 14  DOI:10.1371/journal.pone.0217433  PMID:31181107  PMCID:PMC6557616
    • Bobardt, M., Kuo, J., Chatterji, U., Chanda, S., Little, S. J., Wiedemann, N., Vuagniaux, G., Gallay, P. A. The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate PLoS One  2019 14  DOI:10.1371/journal.pone.0211716  PMID:30716099  PMCID:PMC6361451
    • Gallay, P. A., Chatterji, U., Kirchhoff, A., Gandarilla, A., Pyles, R. B., Baum, M. M., Moss, J. A. Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice The Open Virology Journal  2018 12:1-13  DOI:10.2174/1874357901812010001  PMID:29541273  PMCID:PMC5842390
    • de Wilde, A. H., Zevenhoven-Dobbe, J. C., Beugeling, C., Chatterji, U., de Jong, D., Gallay, P., Szuhai, K., Posthuma, C. C., Snijder, E. J. Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture Virology  2017 517:148-156  DOI:10.1016/j.virol.2017.11.022  PMID:29249267
    • Gallay, P. A., Chatterji, U., Kirchhoff, A., Gandarilla, A., Gunawardana, M., Pyles, R. B., Marzinke, M. A., Moss, J. A., Baum, M. M. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice PLoS One  2017 12  DOI:10.1371/journal.pone.0184303  PMID:28880948  PMCID:PMC5589224
    • Vidotto, A., Morais, A. T., Ribeiro, M. R., Pacca, C. C., Terzian, A. C., Gil, L.H., Mohana-Borges, R., Gallay, P., Nogueira, M. L. Systems biology reveals NS4B-cyclophilin A interaction: A new target to inhibit YFV replication Journal of Proteome Research  2017 16:1542-1555  DOI:10.1021/acs.jproteome.6b00933  PMID:28317380
    • Veazey, R. S., Chatterji, U., Bobardt, M., Russell-Lodrigue, K. E., Li, J., Wang, X., Gallay, P. A. C5A protects macaques from vaginal simian-human immunodeficiency virus challenge Antimicrobial Agents and Chemotherapy  2016 60:693-698  DOI:10.1128/aac.01925-15  PMID:26552985  PMCID:PMC4704173
    • Gallay, P. A., Chatterji, U., Bobardt, M. D., Long, Z., Zhang, S., Su, Z. Characterization of the anti-HCV activities of the new cyclophilin inhibitor STG-175 PLoS One  2016 11  DOI:10.1371/journal.pone.0152036  PMID:27104614  PMCID:PMC4841536
    • Chatterji, U., Bobardt, M., Schaffer, L., Wood, M., Gallay, P. A. Cyclophilin inhibitors remodel the endoplasmic reticulum of HCV-infected cells in a unique pattern rendering cells impervious to a reinfection PLoS One  2016 11  DOI:10.1371/journal.pone.0159511  PMID:27442520  PMCID:PMC4956074
    • Phillips, S., Chokshi, S., Chatterji, U., Riva, A., Bobardt, M., Williams, R., Gallay, P., Naoumov, N. V. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production Gastroenterology  2015 148:403-414  DOI:10.1053/j.gastro.2014.10.004  PMID:25305505
    • Hansson, M. J., Moss, S. J., Bobardt, M., Chatterji, U., Coates, N., Garcia-Rivera, J. A., Elmer, E., Kendrew, S., Leyssen, P., Neyts, J., Nur-E-Alam, M., Warneck, T., et al. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection Chemistry & Biology  2015 22:285-292  DOI:10.1016/j.chembiol.2014.10.023  PMID:25619934  PMCID:PMC4336584
    • Chatterji, U., Bobardt, M., Tai, A., Wood, M., Gallay, P. A. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories Antimicrobial Agents and Chemotherapy  2015 59:2496-2507  DOI:10.1128/aac.04958-14  PMID:25666154
    • Gallay, P. A., Bobardt, M. D., Chatterji, U., Trepanier, D. J., Ure, D., Ordonez, C., Foster, R. The novel cyclophilin inhibitor CPI-431-32 concurrently blocks HCV and HIV-1 infections via a similar mechanism of action PLoS One  2015 10:e0134707  DOI:10.1371/journal.pone.0134707  PMID:26263487  PMCID:PMC4532424
    • Hopkins, S., Gallay, P. A. The role of immunophilins in viral infection Biochimica et Biophysica Acta-General Subjects  2015 1850:2103-2110  DOI:10.1016/j.bbagen.2014.11.011  PMID:25445708  PMCID:PMC4491039
    • Chamoun-Emanuelli, A. M., Bobardt, M., Moncla, B., Mankowski, M. K., Ptak, R. G., Gallay, P., Chen, Z. Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide Antimicrobial Agents and Chemotherapy  2014 58:687-697  DOI:10.1128/aac.02000-13  PMID:24217696  PMCID:PMC3910842
    • Gawlik, K., Gallay, P. A. HCV core protein and virus assembly: what we know without structures Immunologic Research  2014 60:1-10  DOI:10.1007/s12026-014-8494-3  PMID:24557493
    • Gawlik, K., Baugh, J., Chatterji, U., Lim, P. J., Bobardt, M. D., Gallay, P. A. HCV core residues critical for infectivity are also involved in core-NS5A complex formation PLoS One  2014 9:e88866  DOI:10.1371/journal.pone.0088866  PMID:24533158  PMCID:PMC3923060
    • Lim, P. J., Gallay, P. A. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance Current Opinion in Virology  2014 8:30-37  DOI:10.1016/j.coviro.2014.04.012  PMID:24879295  PMCID:PMC4195798
    • Chatterji, U., Garcia-Rivera, J. A., Baugh, J., Gawlik, K., Wong, K. A., Zhong, W., Brass, C. A., Naoumov, N. V., Gallay, P. A. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance Antimicrobial Agents and Chemotherapy  2014 58:3327-3334  DOI:10.1128/aac.00016-14  PMID:24687498  PMCID:PMC4068438
    • Gallay, P. A., Ptak, R. G., Bobardt, M. D., Dumont, J. M., Vuagniaux, G., Rosenwirth, B. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms Viruses-Basel  2013 5:981-997  DOI:10.3390/v5030981  PMID:23524389  PMCID:PMC3705307
    • Lin, K., Gallay, P. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors Antiviral Research  2013 99:68-77  DOI:10.1016/j.antiviral.2013.03.020  PMID:23578729  PMCID:PMC4332838
    • Bobardt, M., Hopkins, S., Baugh, J., Chatterji, U., Hernandez, F., Hiscott, J., Sluder, A., Lin, K., Gallay, P. A. HCV NS5A and IRF9 compete for CypA binding Journal of Hepatology  2013 58:16-23  DOI:10.1016/j.jhep.2012.08.007  PMID:22902549  PMCID:PMC3527675
    • Baugh, J. M., Garcia-Rivera, J. A., Gallay, P. A. Host-targeting agents in the treatment of hepatitis C: A beginning and an end? Antiviral Research  2013 100:555-561  DOI:10.1016/j.antiviral.2013.09.020  PMID:24091203  PMCID:PMC3971122
    • Gallay, P. A., Lin, K. Profile of alisporivir and its potential in the treatment of hepatitis C Drug Design Development and Therapy  2013 7:105-115  DOI:10.2147/dddt.s30946  PMID:23440335  PMCID:PMC3578503
    • Selvarajah, S., Chatterji, U., Kuhn, R., Kinney, R., Vasudevan, S. G., Gallay, P. Development and evaluation of an enzyme-linked immunosorbent assay for dengue capsid The Open Virology Journal  2012 6:29-37  DOI:10.2174/1874357901206010029  PMID:22496714  PMCID:PMC3322434
    • Lim, P. J., Chatterji, U., Cordek, D., Sharma, S. D., Garcia-Rivera, J. A., Cameron, C. E., Lin, K., Targett-Adams, P., Gallay, P. A. Correlation between NS5A dimerization and hepatitis C virus replication Journal of Biological Chemistry  2012 287:30861-30873  DOI:10.1074/jbc.M112.376822  PMID:22801423  PMCID:PMC3436329
    • Gallay, P. A. Cyclophilin inhibitors: A novel class of promising host-targeting anti-HCV agents Immunologic Research  2012 52:200-210  DOI:10.1007/s12026-011-8263-5  PMID:22169996
    • Hopkins, S., Gallay, P. Cyclophilin inhibitors: An emerging class of therapeutics for the treatment of chronic hepatitis C infection Viruses-Basel  2012 4:2558-2577  DOI:10.3390/v4112558  PMID:23202494  PMCID:PMC3509662
    • Baugh, J., Gallay, P. Cyclophilin involvement in the replication of hepatitis C virus and other viruses Biological Chemistry  2012 393:579-587  DOI:10.1515/hsz-2012-0151  PMID:22944661
    • Garcia-Rivera, J. A., Bobardt, M., Chatterji, U., Hopkins, S., Gregory, M. A., Wilkinson, B., Lin, K., Gallay, P. A. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir Antimicrobial Agents and Chemotherapy  2012 56:5113-5121  DOI:10.1128/aac.00919-12  PMID:22802259  PMCID:PMC3457393
    • Chamoun, A. M., Chockalingam, K., Bobardt, M., Simeon, R., Chang, J. H., Gallay, P., Chen, Z. L. PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus Antimicrobial Agents and Chemotherapy  2012 56:672-681  DOI:10.1128/aac.05722-11  PMID:22083468  PMCID:PMC3264232
    • Moss, S. J., Bobardt, M., Leyssen, P., Coates, N., Chatterji, U., Xie, D. J., Foster, T., Liu, J. L., Nur-e-Alam, M., Suthar, D., Chen, Y. S., Warneck, T., et al. Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of hcv infection MedChemComm  2012 3:938-943  DOI:10.1039/c1md00227a
    • Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C. S., Penin, F., Gallay, P. A. Sublimable C5A delivery provides sustained and prolonged anti-hiv microbicidal activities Antimicrobial Agents and Chemotherapy  2012 56:3336-3343  DOI:10.1128/aac.00186-12  PMID:22430971  PMCID:PMC3370808
    • Gunaseelan, S., Gallay, P. A., Bobardt, M. D., Dezzutti, C. S., Esch, T., Maskiewicz, R. Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices Pharmaceutical Research  2012 29:3156-3168  DOI:10.1007/s11095-012-0811-8  PMID:22736232  PMCID:PMC3473190
    • Hopkins, S., Bobardt, M., Chatterji, U., Garcia-Rivera, J. A., Lim, P., Gallay, P. A. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes Antimicrobial Agents and Chemotherapy  2012 56:3888-3897  DOI:10.1128/aac.00693-12  PMID:22585215  PMCID:PMC3393457
    • Hopkins, S., DiMassimo, B., Rusnak, P., Heuman, D., Lalezari, J., Sluder, A., Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., Gallay, P. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection Journal of Hepatology  2012 57:47-54  DOI:10.1016/j.jhep.2012.02.024  PMID:22425702
    • Foster, T. L., Gallay, P., Stonehouse, N. J., Harris, M. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner Journal of Virology  2011 85:7460-7464  DOI:10.1128/jvi.00393-11  PMID:21593166  PMCID:PMC3126559
    • de Witte, L., Bobardt, M. D., Chatterji, U., van Loenen, F. B., Verjans, Gmgm, Geijtenbeek, T. B. H., Gallay, P. A. HSV neutralization by the microbicidal candidate C5A PLoS One  2011 6:e18917  DOI:10.1371/journal.pone.0018917  PMID:21573158  PMCID:PMC3089603
    • Denton, P. W., Othieno, F., Martinez-Torres, F., Zou, W., Krisko, J. F., Fleming, E., Zein, S., Powell, D. A., Wahl, A., Kwak, Y. T., Welch, B. D., Kay, M. S., et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the blt model for evaluation of new microbicide candidates Journal of Virology  2011 85:7582-7593  DOI:10.1128/jvi.00537-11  PMID:21593172  PMCID:PMC3147928
    • Gregory, M. A., Bobardt, M., Obeid, S., Chatterji, U., Coates, N. J., Foster, T., Gallay, P., Leyssen, P., Moss, S. J., Neyts, J., Nur-e-Alam, M., Paeshuyse, J., et al. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family Antimicrobial Agents and Chemotherapy  2011 55:1975-1981  DOI:10.1128/aac.01627-10  PMID:21383094  PMCID:PMC3088210
    • Chatterji, U., Bobardt, M. D., Lim, P., Gallay, P. A. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes Journal of General Virology  2010 91:1189-1193  DOI:10.1099/vir.0.018531-0  PMID:20107018  PMCID:PMC2888154
    • Fischer, G., Gallay, P., Hopkins, S. Cyclophilin inhibitors for the treatment of HCV infection Current Opinion in Investigational Drugs  2010 11:911-918  PMID:20721833
    • Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., Vandamme, A. M., Bartenschlager, R., et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS One  2010 5:e13687  DOI:10.1371/journal.pone.0013687  PMID:21060866  PMCID:PMC2965138
    • Chatterji, U., Lim, P., Bobardt, M. D., Wieland, S., Cordek, D. G., Vuagniaux, G., Chisari, F., Cameron, C. E., Targett-Adams, P., Parkinson, T., Gallay, P. A. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors Journal of Hepatology  2010 53:50-56  DOI:10.1016/j.jhep.2010.01.041  PMID:20451281  PMCID:PMC2884070
    • Bobardt, M. D., Chatterji, U., Schaffer, L., de Witte, L., Gallay, P. A. Syndecan-fc hybrid molecule as a potent in vitro microbicidal anti-hiv-1 agent Antimicrobial Agents and Chemotherapy  2010 54:2753-2766  DOI:10.1128/aac.01606-09  PMID:20439611  PMCID:PMC2897270
    • Waller, H., Chatterji, U., Gallay, P., Parkinson, T., Targett-Adams, P. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A Journal of Virological Methods  2010 165:202-210  DOI:10.1016/j.jviromet.2010.01.020  PMID:20132841
    • Gallay, P. A. Cyclophilin inhibitors Clinics in Liver Disease  2009 13:403-417  DOI:10.1016/j.cld.2009.05.002  PMID:19628157
    • Chatterji, U., Bobardt, M., Selvarajah, S., Yang, F., Tang, H. L., Sakamoto, N., Vuagniaux, G., Parkinson, T., Gallay, P. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication Journal of Biological Chemistry  2009 284:16998-17005  DOI:10.1074/jbc.M109.007625  PMID:19380579  PMCID:PMC2719337
    • Cheng, G., Montero, A., Gastaminza, P., Whitten-Bauer, C., Wieland, S. F., Isogawa, M., Fredericksen, B., Selvarajah, S., Gallay, P. A., Ghadiri, M. R., Chisari, F. V. A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro Proceedings of the National Academy of Sciences of the United States of America  2008 105:3088-3093  DOI:10.1073/pnas.0712380105  PMID:18287023  PMCID:PMC2268589
    • Bobardt, M. D., Cheng, G. F., de Witte, L., Selvarajah, S., Chatterji, U., Sanders-Beer, B. E., Geijtenbeek, T. B. H., Chisari, F. V., Gallay, P. A. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus Proceedings of the National Academy of Sciences of the United States of America  2008 105:5525-5530  DOI:10.1073/pnas.0801388105  PMID:18378908  PMCID:PMC2291127
    • Ptak, R. G., Gallay, P. A., Jochmans, D., Halestrap, A. P., Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., de Bethune, M. P., Neyts, J., De Clercq, E., Dumont, J. M., Scalfaro, P., et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent Antimicrobial Agents and Chemotherapy  2008 52:1302-1317  DOI:10.1128/aac.01324-07  PMID:18212100  PMCID:PMC2292519
    • de Jong, Mawp, de Witte, L., Oudhoff, M. J., Gringhuis, S. I., Gallay, P., Geijtenbeek, T. B. H. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human langerhans cells ex vivo Journal of Clinical Investigation  2008 118:3440-3452  DOI:10.1172/jci34721  PMID:18776939  PMCID:PMC2528910
    • Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, E., Cielniak, I., Higersberger, J., Kierkus, J., Aeschlimann, C., Grosgurin, P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology  2008 47:817-826  DOI:10.1002/hep.22131  PMID:18302285
    • Bobardt, M. D., Chatterji, U., Selvarajah, S. A., Van der Schueren, B., David, G., Kahn, B., Gallay, P. A. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells Journal of Virology  2007 81:395-405  DOI:10.1128/jvi.01303-06  PMID:17050597
    • de Witte, L., Bobardt, M., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T. B. H., Gallay, P. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1 Proceedings of the National Academy of Sciences of the United States of America  2007 104:19464-19469  DOI:10.1073/pnas.0703747104  PMID:18040049  PMCID:PMC2148312
    • Binley, J. M., Ngo-Abdalla, S., Moore, P., Bobardt, M., Chatterji, U., Gallay, P., Burton, D. R., Wilson, I. A., Elder, J. H., de Parseval, A. Inhibition of HIV ENV binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120 Retrovirology  2006 3:39  DOI:10.1186/1742-4690-3-39  PMID:16817962  PMCID:PMC1543650
    • Saphire, A. C. S., Gallay, P. A., Bark, S. J. Proteomic analysis of human immunodeficency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins Journal of Proteome Research  2006 5:530-538  DOI:10.1021/pr050276b  PMID:16512667
    • Chatterji, U., Bobardt, M. D., Gaskill, P., Sheeter, D., Fox, H., Gallay, P. A. Trim5α accelerates degradation of cytosolic capsid associated with productive HIV-1 entry Journal of Biological Chemistry  2006 281:37025-37033  DOI:10.1074/jbc.M606066200  PMID:17028189
    • de Parseval, A., Bobardt, M. D., Chatterji, A., Chatterji, U., Elder, J. H., David, G., Zolla-Pazner, S., Farzan, M., Lee, T. H., Gallay, P. A. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs Journal of Biological Chemistry  2005 280:39493-39504  DOI:10.1074/jbc.M504233200  PMID:16157597
    • Chatterji, U., Bobardt, M. D., Stanfield, R., Ptak, R. G., Pallansch, L. A., Ward, P. A., Jones, M. J., Stoddart, C. A., Scalfaro, P., Dumont, J. M., Besseghir, K., Rosenwirth, B., et al. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells Journal of Biological Chemistry  2005 280:40293-40300  DOI:10.1074/jbc.M506314200  PMID:16199531
    • Barry, S. M., Melar, M., Gallay, P., Hope, T. J. Review of the twelfth west coast retrovirus meeting Retrovirology  2005 2:72  DOI:10.1186/1742-4690-2-72  PMID:16293194  PMCID:PMC1315336
    • Bobardt, M. D., Salmon, P., Wang, L. C., Esko, J. D., Gabuzda, D., Fiala, M., Trono, D., Van der Schueren, B., David, G., Gallay, P. A. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion Journal of Virology  2004 78:6567-6584  DOI:10.1128/jvi.78.12.6567-6584.2004  PMID:15163749
    • Galigniana, M. D., Morishima, Y., Gallay, P. A., Pratt, W. B. Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex Journal of Biological Chemistry  2004 279:55754-55759  DOI:10.1074/jbc.M406259200  PMID:15496417
    • Bobardt, M. D., Armand-Ugon, M., Clotet, I., Zhang, Z., David, G., Este, J. A., Gallay, P. A. Effect of polyanion-resistance on HIV-1 infection Virology  2004 325:389-398  DOI:10.1016/j.virol.2004.05.011  PMID:15246277
    • Gallay, P. Syndecans and HIV-1 pathogenesis Microbes and Infection  2004 6:617-622  DOI:10.1016/j.micinf.2004.02.004  PMID:15158197
    • Bobardt, M. D., Saphire, A. C. S., Hung, H. C., Yu, X. C., Van der Schueren, B., Zhang, Z., David, G., Gallay, P. A. Syndecan captures, protects, and transmits HIV to T lymphocytes Immunity  2003 18:27-39  DOI:10.1016/s1074-7613(02)00504-6  PMID:12530973
    • Yurchenko, V., Zybarth, G., O'Connor, M., Dai, W. W., Franchin, G., Hao, T., Guo, H. M., Hung, H. C., Toole, B., Gallay, P., Sherry, B., Bukrinsky, M. Active site residues of cyclophilin A are crucial for its signaling activity via CD147 Journal of Biological Chemistry  2002 277:22959-22965  DOI:10.1074/jbc.M201593200  PMID:11943775
    • Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Cyclophilin A plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation Journal of Virology  2002 76:4671-4677  DOI:10.1128/jvi.76.9.4671-4677.2002  PMID:11932436
    • Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Trans-complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity Journal of Virology  2002 76:2255-2262  DOI:10.1128/jvi.76.5.2255-2262.2002  PMID:11836403
    • Saphire, A. C. S., Bobardt, M. D., Zhang, Z., David, G., Gallay, P. A. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages Journal of Virology  2001 75:9187-9200  DOI:10.1128/jvi.75.19.9187-9200.2001  PMID:11533182
    • Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells Immunologic Research  2000 21:211-217  DOI:10.1385/ir:21:2-3:211  PMID:10852119
    • Saphire, A. C. S., Bobardt, M. D., Gallay, P. A. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans EMBO Journal  1999 18:6771-6785  DOI:10.1093/emboj/18.23.6771  PMID:10581250  PMCID:PMC1171739
    • Gallay, P., Hope, T., Chin, D., Trono, D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway Proceedings of the National Academy of Sciences of the United States of America  1997 94:9825-9830  DOI:10.1073/pnas.94.18.9825  PMID:9275210
    • Camaur, D., Gallay, P., Swingler, S., Trono, D. Human immunodeficiency virus matrix tyrosine phosphorylation: Characterization of the kinase and its substrate requirements Journal of Virology  1997 71:6834-6841  PMID:9261408  PMCID:PMC191964
    • Swingler, S., Gallay, P., Camaur, D., Song, J. P., Abo, A., Trono, D. The nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix Journal of Virology  1997 71:4372-4377  PMID:9151826  PMCID:PMC191654
    • Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., Trono, D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science  1996 272:263-267  DOI:10.1126/science.272.5259.263  PMID:8602510
    • Gallay, P., Stitt, V., Mundy, C., Oettinger, M., Trono, D. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import Journal of Virology  1996 70:1027-1032  PMID:8551560  PMCID:PMC189908
    • Horadagoda, N. U., Eckersall, P. D., Andrew, L., Gallay, P., Heumann, D., Gibbs, H. A. Characterisation of bovine lipopolysaccharide binding protein and the in vivo acute phase response to Pasteurella haemolytica Type A Veterinary Immunology and Immunopathology  1995 49:61-74  DOI:10.1016/0165-2427(95)05458-i  PMID:8588345
    • Heumann, D., Gallay, P., Le Roy, D., Glauser, M. P. Contribution of lipopolysaccharide binding protein (LBP) in endotoxemic shock in mice Progress in Clinical and Biological Research  1995 392:465-471  PMID:8524953
    • Heumann, D., Bas, S., Gallay, P., Leroy, D., Barras, C., Mensi, N., Glauser, M. P., Vischer, T. Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein Journal of Rheumatology  1995 22:1224-1229  PMID:7562749
    • Gallay, P., Swingler, S., Song, J. P., Bushman, F., Trono, D. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase Cell  1995 83:569-576  DOI:10.1016/0092-8674(95)90097-7  PMID:7585960
    • Gallay, P., Swingler, S., Aiken, C., Trono, D. HIV-1 infection of nondividing cells - C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator Cell  1995 80:379-388  DOI:10.1016/0092-8674(95)90488-3  PMID:7859280
    • Schook, L. B., Albrecht, H., Gallay, P., Jongeneel, C. V. Cytokine regulation of TNF-alpha mRNA and protein production by unprimed macrophages from C57Bl/6 and NZW mice Journal of Leukocyte Biology  1994 56:514-520  PMID:7930949
    • Car, B. D., Eng, V. M., Schnyder, B., Ozmen, L., Huang, S., Gallay, P., Heumann, D., Aguet, M., Ryffel, B. Interferon gamma receptor deficient mice are resistant to endotoxic shock Journal of Experimental Medicine  1994 179:1437-1444  DOI:10.1084/jem.179.5.1437  PMID:8163930  PMCID:PMC2191498
    • Gallay, P., Heumann, D., Leroy, D., Barras, C., Glauser, M. P. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice Proceedings of the National Academy of Sciences of the United States of America  1994 91:7922-7926  DOI:10.1073/pnas.91.17.7922  PMID:7520172  PMCID:PMC44516
    • Heumann, D., Gallay, P., Leroy, D., Landmann, R., Glauser, M. P. Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma Journal of Immunological Methods  1994 171:169-176  DOI:10.1016/0022-1759(94)90037-x  PMID:7515085
    • Corradin, S. B., Heumann, D., Gallay, P., Smith, J., Mauel, J., Glauser, M. P. Bactericidal permeability-increasing protein inhibits induction of macrophage nitric-oxide production by lipopolysaccharide Journal of Infectious Diseases  1994 169:105-111  PMID:8277172
    • Gallay, P., Barras, C., Tobias, P. S., Calandra, T., Glauser, M. P., Heumann, D. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor-necrosis-factor response of monocytes to LPS Journal of Infectious Diseases  1994 170:1319-1322  PMID:7963737
    • Gallay, P., Heumann, D., Leroy, D., Barras, C., Glauser, M. P. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock Proceedings of the National Academy of Sciences of the United States of America  1993 90:9935-9938  DOI:10.1073/pnas.90.21.9935  PMID:7694297  PMCID:PMC47687
    • Gallay, P., Jongeneel, C. V., Barras, C., Burnier, M., Baumgartner, J. D., Glauser, M. P., Heumann, D. Short time exposure to lipopolysaccharide is sufficient to activate human monocytes Journal of Immunology  1993 150:5086-5093  PMID:7684419
    • Heumann, D., Gallay, P., Betzcorradin, S., Barras, C., Baumgartner, J. D., Glauser, M. P. Competition between bactericidal permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes Journal of Infectious Diseases  1993 167:1351-1357  PMID:8501324
    • Gauthier, T., Hamou, M. F., Monod, L., Gallay, P., Carrel, S., Detribolet, N. Expression and release of interleukin-1 by human glioblastoma cells in vitro and in vivo Acta Neurochirurgica  1993 121:199-205  DOI:10.1007/bf01809276  PMID:8512018
    • Gallay, P., Carrel, S., Glauser, M. P., Barras, C., Ulevitch, R. J., Tobias, P. S., Baumgartner, J. D., Heumann, D. Purification and characterization of murine lipopolysaccharide-binding protein Infection and Immunity  1993 61:378-383  PMID:7678583  PMCID:PMC302740
    • Heumann, D., Gallay, P., Barras, C., Zaech, P., Ulevitch, R. J., Tobias, P. S., Glauser, M. P., Baumgartner, J. D. Control of lipopolysaccharide (lps) binding and lps-induced tumor-necrosis-factor secretion in human peripheral-blood monocytes Journal of Immunology  1992 148:3505-3512  PMID:1375247
    • Corradin, S. B., Mauel, J., Gallay, P., Heumann, D., Ulevitch, R. J., Tobias, P. S. Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide (LPS) by LPS-binding protein Journal of Leukocyte Biology  1992 52:363-368  PMID:1402386
    • Gallay, P., Mach, J. P., Carrel, S. Characterization and detection of naturally occurring antibodies against IL-1 alpha and IL-1 beta in normal human plasma Eur Cytokine Netw  1991 2:329-38
    • Carrel, S., Salvi, S., Gallay, P., Rapin, C., Sekaly, R. P. Positive signal transduction via surface cd4 molecules does not need coexpression of the cd3/tcr complex Research in Immunology  1991 142:97-108  DOI:10.1016/0923-2494(91)90017-d  PMID:1678202
    • Carrel, S., Salvi, S., Isler, P., Rapin, C., Hayoz, D., Gallay, P., Giuffre, L. Gp33-38, an early human T-cell activation antigen Journal of Immunology  1990 144:2053-2062  PMID:2138192
  • patent

    • Chisari, F. V., Gallay, P., inventors; Chisari, assignee. Amphipathic antiviral peptides for prevention of infection by measles or respiratory syncytial virus World patent WO2008086042A2 (2008).
scroll to property group menus

Research

research overview

  • Focusing on the Early Steps of the HIV Life Cycle

    HIV has developed sophisticated strategies to enter and survive in human cells. HIV uses multiple host receptors to efficiently penetrate human cells, including CD4, the chemokine receptors CCR5 and CXCR4, and the heparan sulfated syndecans. A major topic of our laboratory is to investigate at a molecular level how and why HIV-1 exploits these distinct receptors to maximize its entry into human cells. 


    Our laboratory also focuses on factors within human cells that attack HIV, immediately after its entry into the cytosol. These human restriction factors target the HIV capsid protein, which comprises the shell that surrounds and protects the viral genome. To circumvent these innate cellular defenses, HIV appears to have evolved the capacity to recruit the host cyclophilin A protein onto its capsid shell in order to successfully infect human cells. A profound understanding of the interplay between HIV and host cell factors is imperative in order to identify novel viral or cellular targets for the development of anti-HIV therapies.

scroll to property group menus

Background

education and training

  • Ph.D., University of Lausanne 1993
scroll to property group menus

Contact

full name

  • Philippe A. Gallay

geographic location

  • Scripps California 

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support